Vaginal changes in menopause span a spectrum from mild dryness to genitourinary syndrome of menopause (GSM) — a chronic, progressive condition caused by declining estrogen and androgen levels that affects the vulva, vagina, urethra, and bladder trigone. It's a hormonal and tissue-level condition, separate from vaginal laxity (a subjective sensation of looseness, often mechanical) and pelvic organ prolapse (structural descent of pelvic organs) — though the three can coexist in the same woman. Unlike hot flashes, GSM tends to persist and even progress without treatment — but low-dose vaginal estrogen, vaginal DHEA, ospemifene, and non-hormonal moisturizers each have trial evidence behind them.
📚 Articles in This Cluster
Key Takeaways
- Genitourinary syndrome of menopause (GSM) is the clinical term for the vulvar, vaginal, urinary, and sexual symptoms caused by estrogen and androgen loss around menopause, and it is distinct from vaginal laxity and pelvic organ prolapse, which are mechanical or support-related changes, not primarily hormonal ones (AUA/SUFU/AUGS 2025 Guideline).
- Low-dose vaginal estrogen has the strongest evidence base for GSM and carries a Strong Recommendation from AUA/SUFU/AUGS, with minimal systemic absorption at approved doses.
- Vaginal moisturizers and lubricants remain reasonable first-line, low-risk options, though a 2024 systematic review for the guideline rated their benefit as low-certainty evidence — helpful for many women, but not equivalent in strength to hormonal therapy.
- Vaginal DHEA (prasterone) and oral ospemifene are FDA-approved, non-estrogen options for moderate-to-severe GSM, each with a distinct mechanism and safety profile worth discussing individually with a clinician.
- For breast cancer survivors, GSM care requires shared decision-making with oncology input rather than a one-size-fits-all rule — the 2025 guideline explicitly addresses this population.
- Current evidence does not support CO2 or Er:YAG laser, or radiofrequency devices, as an established treatment for GSM; guidelines classify these as investigational outside a clinical trial setting.
Vaginal Changes in Menopause: An Honest Introduction
Somewhere between the last period and the first honest conversation about it, a lot of women go quiet. Vaginal dryness, a stinging feeling after sex, a strange new urgency to urinate that wasn't there five years ago — these are common vaginal changes in menopause, yet they rarely come up at the dinner table, and sometimes not even in the exam room unless a patient forces the issue.
That silence has a cost. Left unaddressed, these symptoms tend to worsen, because unlike hot flashes, genitourinary syndrome of menopause (GSM) doesn't usually fade on its own once estrogen has been low for a while. Here's the more useful truth: GSM, vaginal laxity, and pelvic organ prolapse are three different things often lumped together under "menopause down there," and each has its own evaluation and evidence-based options. Confusing them leads to the wrong conversation with the wrong specialist, or worse, to unproven treatments sold as answers to a question never properly asked.
This guide separates the strands: what GSM is, how it differs from laxity and prolapse, and what current guidance from the American Urological Association, SUFU, and the American Urogynecologic Society (AUA/SUFU/AUGS) recommends for 2025 and beyond.
If painful sex, dryness, or urinary symptoms are affecting your life, a focused pelvic assessment is the right next step. Our evidence-based approach to vaginal dryness and laxity starts there.
Quick Overview
Vaginal changes in menopause span a spectrum from mild dryness to genitourinary syndrome of menopause (GSM) — a chronic, progressive condition caused by declining estrogen and androgen levels that affects the vulva, vagina, urethra, and bladder trigone. GSM commonly produces dryness, burning, itching, dyspareunia (painful sex), urinary urgency, and recurrent urinary tract infections. It's a hormonal and tissue-level condition, separate from vaginal laxity (a subjective sensation of looseness, often mechanical) and pelvic organ prolapse (structural descent of pelvic organs) — though the three can coexist in the same woman.
The good news: GSM is one of the more treatable parts of the menopause transition. Unlike hot flashes, which often resolve within a few years, GSM tends to persist and even progress without treatment — but low-dose vaginal estrogen, vaginal DHEA, ospemifene, and non-hormonal moisturizers each have trial evidence behind them, and a clinician can match the option to your history, preferences, and risk factors, including a personal history of breast cancer.
Understanding the Condition: What GSM Actually Is
Genitourinary syndrome of menopause is a name introduced in 2014 by consensus between the International Society for the Study of Women's Sexual Health and The Menopause Society, replacing the older term "vulvovaginal atrophy." The rename mattered clinically: it folded urinary symptoms — urgency, dysuria, recurrent UTIs — into the same hormonal picture as vaginal dryness and painful sex, since estrogen and androgen receptors are distributed across the vulva, vagina, urethra, and bladder base, not just the vaginal walls.
The 2025 AUA/SUFU/AUGS guideline, endorsed by ISSWSH, the Sexual Medicine Society of North America, and The Menopause Society, is the first comprehensive, multi-society clinical guideline built specifically around GSM. It defines the condition around patient-reported symptoms — with or without corroborating exam findings — after other causes are ruled out, and makes 26 recommendations spanning screening, diagnosis, and treatment.
Two things distinguish GSM from a passing symptom: it's chronic and progressive — dryness and thinning tend to worsen over years without treatment — and it responds well to targeted, local therapy in most cases, which is why guideline authors emphasize screening rather than waiting for women to volunteer symptoms they may feel embarrassed to raise.
Anatomy and Physiology: Why Estrogen Loss Changes So Much
Estrogen keeps the vaginal lining thick, well-supplied with blood, and rich in glycogen — a sugar that resident lactobacilli convert into lactic acid, keeping a premenopausal vagina acidic (roughly pH 3.8–4.5) and relatively resistant to infection. When estrogen falls, that whole system downshifts: the epithelium thins from a many-layered, glycogen-rich tissue to a fragile few-cell-layer lining, blood flow drops so tissues heal more slowly and tear more easily during sex, and vaginal pH rises toward 5–7, shifting the microbiome toward organisms associated with irritation and infection. Collagen and elastin in the vaginal wall also change, and the rugae — the folds that give a healthy vaginal wall its elasticity — flatten out.
None of this is the same physiology as vaginal laxity from childbirth-related fascial stretch, or pelvic organ prolapse from weakened ligamentous support. GSM is hormonal and mucosal; laxity and prolapse are largely structural and mechanical. They can and often do occur in the same woman at once, which is exactly why "it feels different down there" cannot be diagnosed from a checklist alone.
Symptoms Across Four Domains: Vulvar, Vaginal, Urinary, Sexual
The 2025 guideline organizes GSM symptoms into four overlapping domains, worth reading separately rather than as one long list.
Vulvar symptoms: itching, burning, or a raw sensation, sometimes mistaken for a yeast infection; loss of labial fullness and flattening of the labia minora; fragile skin that fissures or bleeds with friction or tight clothing.
Vaginal symptoms: dryness, described by patients as "sandpaper" or a persistent tight feeling; burning, especially with urination or sexual activity; loss of elasticity and flattening of the rugae, visible on exam; increased susceptibility to microtrauma and postcoital spotting; watery or malodorous discharge from a shifted vaginal microbiome.
Urinary symptoms: urgency and frequency without infection; dysuria — burning or discomfort with urination; recurrent UTIs, sometimes the first sign a clinician recognizes as GSM rather than "just bad luck"; mild stress incontinence that can overlap with, but isn't caused by, GSM alone.
Sexual symptoms: dyspareunia — pain with penetration, often described as tearing or a "hitting a wall" sensation; reduced arousal and lubrication response; avoidance of intimacy driven by anticipated pain rather than loss of desire.
A short warning list sits alongside these: unexpected postmenopausal bleeding, a rapidly enlarging vulvar lesion, non-healing ulceration, or fever with pelvic pain are not typical GSM findings and need prompt evaluation.
GSM vs Vaginal Laxity vs Pelvic Organ Prolapse: Why the Distinction Matters
Getting this table wrong sends patients toward the wrong treatment entirely.
| Feature | GSM | Vaginal Laxity | Pelvic Organ Prolapse |
|---|---|---|---|
| What it is | Hormone-driven thinning, dryness, and irritation of vulvovaginal and lower urinary tract tissue | A subjective sensation of vaginal looseness or reduced friction, often multifactorial | Structural descent of the bladder, uterus, rectum, or vaginal apex into or beyond the vaginal canal |
| Primary driver | Estrogen/androgen decline | Childbirth-related fascial stretch, connective-tissue aging, mechanical factors | Weakened ligamentous and fascial support |
| Typical symptoms | Dryness, burning, dyspareunia, urgency, recurrent UTI | Reduced tactile sensation, "looseness," occasionally vaginal air escaping during movement | Bulge sensation, pelvic pressure or heaviness, a visible or palpable protrusion |
| Exam findings | Pale, thin, fragile mucosa; loss of rugae; elevated pH | Wider vaginal introitus without organ descent; may have normal or reduced pelvic floor tone | Descent of anterior/posterior wall or apex on straining, staged with POP-Q |
| First-line management | Moisturizers/lubricants, then low-dose vaginal estrogen, vaginal DHEA, or ospemifene | Pelvic floor muscle training with a specialist physiotherapist; individualized assessment | Pelvic floor muscle training, pessary, then surgical evaluation if appropriate |
The overlap is real: a woman with severe atrophic dryness may describe her vagina as "loose" simply because reduced lubrication changes tactile feedback, not because fascial support failed. A woman with true prolapse may also have GSM-driven dryness on top, and treating the dryness won't resolve the bulge. Sorting out which is which is the point of an in-person assessment.
Causes and Risk Factors
GSM's principal cause is hypoestrogenism: the natural, permanent decline in circulating estradiol after the final menstrual period, sometimes accelerated by surgical menopause, chemotherapy, or medications such as aromatase inhibitors used in breast cancer treatment. A handful of factors influence how quickly and severely symptoms appear: time since menopause — symptoms generally worsen the longer a woman goes without treatment, since tissue changes are progressive; smoking — nicotine's antiestrogenic and vasoconstrictive effects appear to worsen atrophy and slow healing; lack of sexual activity or vaginal stimulation — regular activity or vaginal dilator use is associated with better-preserved elasticity and blood flow; antiestrogen cancer therapy — aromatase inhibitors, tamoxifen, and GnRH agonists markedly lower estrogen exposure and often produce more severe GSM than natural menopause alone; diabetes and immunosuppression — these can compound mucosal fragility and infection risk; and parity is not protective — GSM affects women regardless of delivery history, unlike laxity or prolapse.
None of these are things a woman did "wrong." They mainly help tailor counseling: someone on an aromatase inhibitor needs a more careful conversation about vaginal estrogen than someone with natural, uncomplicated menopause.
Diagnosis and Clinical Assessment
A GSM work-up isn't complicated, but it should be systematic rather than assumed from a symptom description alone: a focused history covering timing of menopause, symptoms across all four domains, sexual activity and pain patterns, current medications, and prior treatments tried; a genitourinary examination inspecting for labial resorption, loss of rugae, pallor, fragility, and urethral changes; ruling out mimics — postmenopausal bleeding, suspicious lesions, or infection signs are evaluated separately, not assumed to be "just GSM"; screening for coexisting conditions, with a pelvic floor assessment or POP-Q staging added if laxity or prolapse symptoms are also present; and, occasionally, vaginal pH or maturation index in research settings, though diagnosis in practice is primarily clinical.
What this assessment explicitly isn't: a decision that surgery, laser, or any specific product is "needed" based on appearance alone. The guideline emphasizes diagnosing from bothersome symptoms plus exam findings — not treating an asymptomatic finding just because it exists.
Treatment and Management by Evidence Strength
The 2025 guideline deliberately avoids ranking every hormonal option in a strict step-1, step-2, step-3 order, because there is insufficient information to recommend one hormonal therapy over another — instead calling for shared decision-making based on the individual's goals and risk profile.
Non-hormonal moisturizers and lubricants
These remain a reasonable starting point, particularly for women with mild symptoms, those who prefer to avoid hormonal treatment, and breast cancer survivors, for whom they're considered first-line. Lubricants are used at the time of intercourse to reduce friction; moisturizers are applied regularly (often two to three times weekly) to maintain baseline hydration. Worth being precise here rather than overselling it: a 2024 systematic review conducted for the guideline rated moisturizer evidence as low-certainty for improving dryness, with uncertain benefit for dyspareunia specifically. A 2018 randomized trial even found that neither a low-dose vaginal estradiol tablet nor an over-the-counter moisturizer outperformed placebo gel, suggesting consistent use may matter more than which product is chosen. That doesn't make moisturizers useless — it means they're a reasonable option, not a guaranteed fix.
Low-dose vaginal estrogen therapy
This has the most robust trial evidence of any GSM treatment and carries a Strong Recommendation for improving dryness, irritation, and dyspareunia, plus a Moderate Recommendation for reducing recurrent UTIs. It's available as a cream, vaginal tablet or insert, or a slow-release ring. At approved low doses, systemic estradiol absorption stays close to normal postmenopausal levels — which is why a progestin isn't required to protect the endometrium at these doses. Long-term use is common and expected to continue for as long as symptoms persist, since GSM tends to recur once treatment stops.
Vaginal DHEA (prasterone)
FDA-approved as a daily 6.5 mg vaginal insert, prasterone is metabolized locally into estrogen and androgen within vaginal tissue — an "intracrine" mechanism that keeps serum hormone levels within the normal postmenopausal range even with consistent use. Trials show meaningful improvement in dyspareunia and dryness versus placebo, with endometrial safety demonstrated through 52 weeks. It's a useful non-estrogen-labeled alternative for women who want to avoid an "estrogen" product on principle, even though its downstream effect is partly estrogenic at the tissue level.
Oral ospemifene
Ospemifene is a selective estrogen receptor modulator (SERM) taken as a daily 60 mg tablet, FDA-approved for moderate-to-severe dyspareunia due to menopausal vulvovaginal atrophy. A pooled safety analysis across six phase III trials found no unexpected signal on the breast, endometrium, or cardiovascular system, with hot flushes as the most common side effect. Being oral and non-local, it may suit women who dislike applicators or have limited hand dexterity, though risk factors should still be reviewed with a clinician first.
Pelvic floor physical therapy
Not GSM-specific, but relevant when dyspareunia has caused reflexive pelvic floor guarding, or when laxity/urinary symptoms coexist. Supervised pelvic floor muscle training remains foundational for laxity- and continence-related symptoms, distinct from but sometimes complementary to GSM treatment.
A note on expectations: none of these options "tighten" the vagina structurally — they restore tissue health, hydration, and comfort. If your primary concern is looseness rather than dryness or pain, that's a different conversation, covered in our pillar guide to vaginal laxity.
Treatment Comparison Table
| Option | Mechanism | Evidence Strength | Typical Timeline |
|---|---|---|---|
| Vaginal moisturizers/lubricants | Surface hydration and reduced friction | Low-certainty for dryness; first-line for breast cancer survivors | Immediate, ongoing use |
| Low-dose vaginal estrogen | Restores epithelial thickness, vascularity, and pH | Strong Recommendation (Grade C for symptoms; Grade B for recurrent UTI) | 4–12 weeks for symptom relief |
| Vaginal DHEA (prasterone) | Local intracrine conversion to estrogen/androgen | FDA-approved; supported by multiple guidelines for moderate-severe GSM | 4–12 weeks |
| Oral ospemifene | Selective estrogen receptor modulator (SERM) | FDA-approved for moderate-severe dyspareunia; large phase III trial base | 4–12 weeks |
| Pelvic floor physical therapy | Neuromuscular retraining, not hormonal | Strong for laxity/continence symptoms; adjunctive for GSM-related pelvic guarding | 8–12 weeks |
| CO2/Er:YAG laser or radiofrequency | Thermal/ablative stimulation of collagen remodeling | Evidence does not support routine use; investigational outside clinical trials | Variable, unproven |
Shared Decision-Making for Breast Cancer Survivors
This deserves its own section, because it's one of the areas the 2025 guideline addresses directly, and where blanket rules do the most harm. Breast cancer survivors experience GSM at high rates, often more severely than women with natural menopause, largely because adjuvant therapies such as aromatase inhibitors and tamoxifen intentionally suppress estrogen activity.
The guideline's approach is not "never use hormones" or "always use hormones" — it's individualized. Non-hormonal moisturizers remain first-line for this group. When symptoms are moderate to severe and don't respond to non-hormonal measures, considering vaginal estrogen or DHEA should happen through explicit shared decision-making that weighs symptom severity against theoretical recurrence risk, ideally with oncology input. A 2022 study of prasterone in breast cancer survivors on aromatase inhibitors found meaningful symptom and sexual-health improvement with serum estradiol remaining low — reassuring, but not a blanket clearance; the decision still needs to be made case by case with the treating oncologist.
The North American Menopause Society's 2022 position statement echoes this caution while naming low-dose vaginal estrogen, DHEA, and ospemifene as options that may be considered when non-hormonal therapy fails and the patient, after consulting her oncologist, chooses to proceed fully informed of risks and benefits. If you're a breast cancer survivor reading this: these options aren't off the table. The decision belongs to you, made with your oncologist and gynecologic clinician together.
Where the Evidence Stands on Laser and Radiofrequency
Energy-based devices — fractional CO2 laser, Er:YAG laser, and radiofrequency — have been marketed for years as vaginal "rejuvenation" or GSM treatments. It's worth being direct about what the evidence shows, rather than what the marketing implies.
The 2025 AUA/SUFU/AUGS guideline states plainly that current evidence does not demonstrate the efficacy of energy-based therapies (CO2 or Er:YAG laser) for GSM symptoms, and classifies these technologies as experimental outside a clinical trial. This isn't an isolated opinion: a 2025 analysis in Climacteric reviewing seven sham-controlled randomized trials concluded the laser should not be used in a clinical context for GSM until meaningful benefit is shown in a properly powered study, and a separate meta-analysis of sham-controlled RCTs reached the same conclusion — no significant benefit over sham across sexual function, vaginal health, and pain scores. Earlier observational studies had reported positive results, but those findings haven't held up as sham controls were introduced.
The same caution applies to radiofrequency for vaginal laxity: a 2024 meta-analysis found pooled observational data suggested improved sexual function scores, but that benefit disappeared when restricted to the three available RCTs, with no significant improvement in subjective laxity scores versus sham.
None of this means laser or radiofrequency can never be discussed. The guideline allows CO2 laser to be considered, as expert opinion, for a patient who isn't a candidate for FDA-approved GSM treatments — but only after a transparent conversation about the uncertainty, not as a routine offering. This clinic does not offer vaginal laser or radiofrequency treatment. Any clinic offering it should be transparent about the evidence gap rather than presenting it as proven.
This clinic also does not promote platelet-rich plasma (PRP) injections or polydioxanone (PDO) thread placement for vaginal dryness, laxity, or GSM symptoms. Published data on these approaches for genital indications remain limited to small pilot studies and case series — nowhere near the evidence behind vaginal estrogen, DHEA, or ospemifene. Presenting either as a proven fix would overstate what the literature supports.
If you've been offered laser, RF, PRP, or thread treatments elsewhere for menopausal dryness or laxity and want a second opinion grounded in current guidance, our safe-treatment assessment pathway starts with figuring out what's actually causing your symptoms.
Recovery, Self-Care and Realistic Timelines
Most GSM treatments work gradually, not overnight. Setting expectations avoids the common frustration of stopping too early. In weeks 1–2, moisturizers and lubricants offer immediate, short-term comfort during use, but consistent near-daily use is needed before cumulative benefit in baseline hydration appears. By weeks 2–4, vaginal estrogen, DHEA, and ospemifene typically begin showing measurable improvement in dryness and burning; full benefit for dyspareunia often takes longer. Most clinical trials measure outcomes at the 4–12 week mark — a reasonable point to reassess with your clinician whether treatment is working or needs adjustment. Ongoing: GSM is chronic. Guideline authors are explicit that long-term treatment is usually required — stopping once symptoms improve commonly leads to recurrence, since the underlying hormonal environment hasn't changed.
Beyond medication, a few habits support comfort: avoiding scented soaps or douches that strip protective secretions; maintaining regular sexual activity or vaginal stimulation where comfortable, since this appears to support tissue perfusion; and staying well hydrated.
Prevention and Long-Term Maintenance
Menopause itself can't be prevented, but GSM severity isn't fixed. Two things matter most for long-term comfort: catching it early, and staying consistent. Early recognition beats late intervention — GSM tends to progress rather than plateau, so addressing mild dryness before it becomes painful sex or recurrent infections is easier and usually needs less intensive treatment than waiting years. Consistency matters more than choice of product — whether the plan involves a moisturizer, vaginal estrogen, DHEA, or ospemifene, the evidence base comes from studies where women used the product as directed, consistently, over 12 weeks or more. Sporadic use is unlikely to reproduce trial-level results.
Myths and Facts
Myth: Vaginal dryness after menopause is just something you have to live with.
Fact: GSM is a recognized, treatable condition with multiple evidence-based options — not an inevitable consequence of aging.
Myth: Vaginal estrogen is dangerous because it's "hormones."
Fact: At approved low doses, vaginal estrogen produces minimal systemic absorption, and guidelines don't require added progestin to protect the endometrium at these doses.
Myth: If you have GSM, your vagina is also "loose," and vice versa.
Fact: GSM is hormonal and mucosal; vaginal laxity is mechanical and structural. They can coexist, but treating one doesn't automatically resolve the other.
Myth: Laser or radiofrequency treatments are a proven, FDA-approved fix for vaginal dryness.
Fact: Current high-quality trial evidence doesn't support these devices for GSM; major guidelines classify them as investigational outside research settings.
Myth: Breast cancer survivors can never use vaginal hormone therapy.
Fact: Non-hormonal options are first-line, but some survivors with moderate-to-severe symptoms may consider vaginal estrogen or DHEA through shared decision-making with oncology input.
Myth: Any moisturizer or lubricant works the same as prescription treatment.
Fact: Moisturizers and lubricants provide real, low-risk relief, but the evidence certainty is lower than for vaginal estrogen, DHEA, or ospemifene, particularly for pain during sex.
🚩 Red Flags: When to Seek Care Promptly
- Any postmenopausal vaginal bleeding or spotting, even minor
- A vulvar lesion, ulcer, or lump that doesn't heal within a couple of weeks
- Fever, severe pelvic pain, or foul-smelling discharge
- New or worsening urinary retention, or inability to fully empty the bladder
- A visible bulge or protrusion at or beyond the vaginal opening, which may indicate prolapse rather than GSM alone
None of these are typical GSM features, and they warrant prompt evaluation rather than a trial of home remedies.
Related Conditions and Sibling Pages
- Vaginal Laxity: Causes, Assessment and Evidence-Based Options — our pillar guide separating laxity from GSM and prolapse.
- Vaginal Laxity and Urinary Incontinence — related but distinct urinary conditions that can overlap with GSM's urinary symptoms.
- Vaginal Changes After Childbirth.
Related reading: Vaginal Dryness & GSM. For confirmed clinical service information, see the cosmetic gynecology service page.
Frequently Asked Questions
What is genitourinary syndrome of menopause (GSM)?
GSM is the clinical term for vulvar, vaginal, urinary, and sexual symptoms caused by declining estrogen and androgen levels around menopause, including dryness, burning, dyspareunia, and urinary urgency.
Is vaginal dryness after menopause the same thing as vaginal laxity?
No. Vaginal dryness after menopause is usually part of GSM, a hormonal and mucosal change. Vaginal laxity is a separate, largely mechanical sensation of looseness that can occur with or without GSM.
Is painful sex after menopause normal, and does it need treatment?
Painful sex after menopause is common, driven mainly by atrophic tissue changes and reduced lubrication, but it is not something you have to accept — it typically responds well to moisturizers, vaginal estrogen, DHEA, or ospemifene.
Is vaginal estrogen safe for long-term use?
At approved low doses, vaginal estrogen produces minimal systemic absorption, and current guidance supports long-term use for as long as symptoms persist, without needing added progestin at these doses.
Can breast cancer survivors use vaginal estrogen or DHEA?
Non-hormonal moisturizers are first-line for breast cancer survivors. For moderate-to-severe symptoms unresponsive to non-hormonal care, vaginal estrogen or DHEA may be considered on an individual basis through shared decision-making with the treating oncologist.
Do vaginal laser or radiofrequency treatments work for GSM?
Current sham-controlled randomized trial evidence does not support CO2/Er:YAG laser or radiofrequency as effective GSM treatments; major guidelines classify them as investigational outside clinical trials.
Conclusion
The vocabulary matters more than it might seem. "Vaginal changes in menopause" isn't one condition — it's a set of overlapping but distinguishable issues, and GSM, vaginal laxity, and pelvic organ prolapse each have their own evidence base and treatment pathway. The 2025 AUA/SUFU/AUGS guideline gives a genuinely useful, current framework: screen for symptoms, examine rather than assume, start with the lowest-risk effective option, and individualize decisions — especially for breast cancer survivors — rather than follow a fixed script. What it doesn't support is treating unproven energy-based devices, PRP, or PDO threads as established GSM therapy, however appealing the marketing sounds.
If this describes what you've been experiencing quietly, the first useful step isn't picking a treatment off this page — it's a proper assessment that sorts out what's actually happening. Book a confidential consultation through our evidence-based dryness and laxity assessment pathway, where the conversation starts with your symptoms and history — not with a procedure already decided in advance.
References
- Kaufman MR, Ackerman LA, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 2025;214(3):242-250.
- American Urological Association. American Urological Association Releases New Guideline on Genitourinary Syndrome of Menopause. Press release. 2025.
- Nanavati M, et al. Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review. Ann Intern Med. 2024;177(10).
- Pereira GMV, Cartwright R, Juliato CRT, Domoney C, Iglesia CB, Brito LGO. Treatment of women with vaginal laxity: systematic review with meta-analysis. J Sex Med. 2024;21(5):430-442.
- Laser for genitourinary syndrome of menopause: what we know and what we don't. Climacteric. 2025.
- Carbon dioxide laser therapy for the management of genitourinary syndrome of menopause: A meta-analysis of randomized controlled trials.
- American College of Obstetricians and Gynecologists (ACOG). Pelvic Organ Prolapse. ACOG Practice Bulletin No. 214. Obstet Gynecol. 2019;134(5):e126-e142.
- National Institute for Health and Care Excellence (NICE). Pelvic Floor Dysfunction. NICE Guideline NG210. 2021.
- The Menopause Society (NAMS). 2022 Hormone Therapy Position Statement. Menopause. 2022.
- International Society for the Study of Women's Sexual Health / The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement. 2020.
- Melisko ME, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors. 2022.
- Mitchell CM, Reed SD, Diem S, et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms. JAMA Intern Med. 2018.